Exogenous and Endogenous Dendritic Cell-Derived Exosomes: Lessons Learned for Immunotherapy and Disease Pathogenesis

Area of Science:

• Immunology
• Cell Biology
• Therapeutics

Background:

• Exosomes derived from dendritic cells (DCs) are being explored for immune therapies.
• These exosomes can be engineered for targeted delivery of immunomodulatory molecules.
• Understanding exosome biogenesis, uptake, and biodistribution is crucial for therapeutic development.

Purpose of the Study:

• To review the therapeutic potential of exogenous DC-derived exosomes.
• To discuss the pathogenic role of endogenous exosomes in disease.
• To highlight the need for understanding exosome mechanisms in vivo.

Main Methods:

• Literature review of clinical trials and mechanistic studies on exosomes.
• Analysis of exosome biogenesis, secretion, and cellular uptake pathways.
• Examination of the role of cellular stressors in endogenous exosome production.

Main Results:

• Exogenous DC-derived exosomes demonstrate favorable safety and tolerance in early clinical trials.
• Endogenous exosomes, particularly those associated with the senescence-associated secretory phenotype (SASP), can amplify inflammatory signaling.
• Cell stressors like microbes and reactive oxygen species influence endogenous exosome content and function.

Conclusions:

• Exosomes represent a versatile platform for immune-based therapies.
• Pathogenic endogenous exosomes contribute to chronic inflammation and tumorigenesis.
• Further research into exosome biology is essential for both therapeutic advancement and understanding disease pathogenesis.